Modern nano-biotech and life science strive to understand life on a molecular level and attempt to predict diseases.
     
    Mass spectrometers have become one of the most important tool in that effort.
     
    GEMIO Technologies, Inc. is creating next generation ion sources for biological macromolecules which will enable unprecedented sensitivity levels of mass spectrometric analysis. 

     
    _____

    News:
    September 2008: Stanford University (School of Medicine) and GEMIO team-up to continue R&D on advanced ion sources and to validate the clinical utility of GEMIO's technology.


    News:
    June 2008: GEMIO has been selected to present its technology at the 2008 TechConnect Summit during the 2008 NSTI Nanotech conference, the largest and most comprehensive technical and business event in nanotechnology world-wide.

    http://www.nsti.org/Nanotech2008/showabstract.html?absno=22048
    http://www.nsti.org/Nanotech2008

    TechConnect Summit is a showcase of prescreened, advanced technologies and early stage companies specifically in nanotech, cleantech and biotech. At the Summit, IP, seed and early-stage companies meet with corporations and investors to match-up funding or partnering opportunities while large corporations present their current and future technology needs.

    News:
    November 8 2007: GEMIO's CEO speaks at an event on
    Personalized Medicine, Companion Diagnostics, and Biomarkers
    organizd by the German-American Business Association about
    "Instruments for reliable biomarker discovery"
    www.gaba-network.org...

     
    _____

    News:
    The largest German Business News Magazine "Wirtschaftswoche" ("BusinessWeek") www.wiwo.de (comparable to The Economist and Business Week), features in issue 11/2007 an one page article entitled

    "The building blocks of Life"

    about GEMIO Technologies, its founder Dr. Andreas Hieke, and the relevance of this technology for early stage molecular cancer detection.   English pdf     German pdf

    _____